Key facts
- Hill Research’s last known valuation is $50.0M (Oct 2025).
- It has raised $20.3M; the latest was Seed Round ($20.0M) in Oct 2025.
- Notable investors include Alumni Ventures, HSG (Hong Kong), Miracleplus, Covenant Venture Capital, Innovation and Technology — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Hill Research
- ·The full record, as it builds
Funding rounds
No funding rounds for Hill Research are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hill Research
Developer of an AI-based healthcare platform designed to accelerate clinical trials for pharmaceutical companies. The company's platform provides AI-driven methods, including intelligent decision support, compliance optimization, and safety predictions, streamlines trial operations, and increases drug approval success rates and also offers a statistical programming platform to solve complex clinical data and documentation challenges, enabling medical professionals to shorten clinical trial cycles and simplify their operations.
- Sector
- Healthcare
- HQ
- Princeton, NJ, United States
- Founded
- 2022
- Employees
- 25
- Website
- hillresearch.ai/
- Ownership
- Privately Held (backing)
Hill Research doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hill Research shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hill Research in its N-PORT filings yet. We sweep new filings monthly.